|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.680 USD | -5.64% |
|
-4.17% | +7.92% |
| 08-06 | LifeMD, Inc., Q2 2026 Earnings Call, Aug 05, 2026 | |
| 06-22 | LifeMD, Inc. And Antares Pharma, Inc. Launch Direct-To-Patient Self-Pay Program For XYOSTED (Testosterone Enanthate) Injection | CI |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Neutral | Neutral |
| Resistance | 4.13 | 5.27 | 6.97 |
| Spread/Res. | -10.90% | -30.17% | -47.20% |
| Spread/Supp. | +5.14% | +39.39% | +37.83% |
| Support | 3.5 | 2.64 | 2.67 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- LFMD Stock
- Charts LifeMD, Inc.
Select your edition
All financial news and data tailored to specific country editions
